英文：Toll-like receptor signalling associated with immunomodulation of umbilical cord-derived mesenchymal stem cells in mice with systemic lupus erythematosus
作者：兒童部 趙玉華 醫師
|本篇論文發表於Lupus期刊2020 (Feb): 29 (2): 165-175 全文下載
With potent immunomodulatory activities, mesenchymal stem cells (MSCs) have the potential to be a beneficial treatment option for diseases with aberrant immune responses such as systemic lupus erythematosus (SLE). However, the underlying mechanisms remain largely unknown. Here, we used NZBWF1 mice as a SLE animal model to examine immunomodulation of MSCs as well as to assess the role of Toll-like receptor signaling in this circumstance. We found that mice receiving MSCs had a significant decrease in severity of proteinuria at 20 and 22 weeks of age (P = 0.009 and P = 0.022, respectively). Serum anti-dsDNA levels were significantly lower compared to the control group (P = 0.016 and P = 0.036, respectively). C3 and C4 levels were significantly higher at 22 weeks of age (P = 0.046 and P = 0.016, respectively). Altered expression of inflammation-associated cytokine profiles in the serum was also noted in mice receiving MSCs. Downregulation of MyD88-NFκB signaling in the liver was demonstrated by Q-PCR, ELISA, and Western blotting. In addition to demonstrating the beneficial effects of MSC treatment in NZBWF1 mice, our study provided the first evidence for the association of MyD88-NFκB signaling and MSC-mediated immunomodulation in this disease.